La vendita allo scoperto per Ironwood Pharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Ironwood Pharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Ironwood Pharmaceuticals (NASDAQ:IRWD) Azioni, Report sulle vendite allo scoperto

Ironwood Pharmaceuticals

Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals Inc

<h3>Gainers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares moved upwards by 67.4% to $0.02 during Tuesday's pre-market session. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares increased by 39.22% to $39.65. The company's market cap stands at $8.8 billion. </li>
<li>LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) stock rose 19.83% to $7.31. The company's market cap stands at $325.9 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock increased by 15.71% to $0.07. The market value of their outstanding shares is at $1.6 million. </li>
<li>Aardvark Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AARD#NASDAQ">AARD</a>) stock increased by 15.61% to $11.7. The company's market cap stands at $250.1 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares rose 14.14% to $1.07. The market value of their outstanding shares is at $187.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) shares decreased by 20.7% to $1.0 during Tuesday's pre-market session. The company's market cap stands at $34.5 million. </li>
<li>Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) stock fell 14.51% to $0.31. The company's market cap stands at $10.1 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock fell 14.06% to $0.25. The market value of their outstanding shares is at $3.4 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock fell 13.45% to $5.15. The company's market cap stands at $78.4 million. </li>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock declined by 11.32% to $0.86. The company's market cap stands at $137.7 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares declined by 9.16% to $3.31. The market value of their outstanding shares is at $85.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AARD

CYCC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IRWD

ITRM

LFMD

LGMK

PTPI

RLMD

SNTI

TVGN

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

News

Guidance

Ironwood Pharmaceuticals Raises 2025 Adj. EBITDA Guidance To Over $105M

Wells Fargo analyst Mohit Bansal downgrades Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) from Overweight to Equal-Weight and lowers the price target from $7 to $1.

Downgrades

Price Target

Analyst Ratings

Wells Fargo Downgrades Ironwood Pharmaceuticals to Equal-Weight, Lowers Price Target to $1

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barclays analyst Dan Levy downgraded the rating for General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) from Overweight to Equal-Weight and lowered the price target from $70 to $40. General Motors shares closed at $45.14 on Monday. <a href="https://www.benzinga.com/quote/GM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Michael Ha downgraded HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) from Outperform to Neutral and cut the price target from $396 to $336. HCA Healthcare shares closed at $340.62 on Monday. <a href="https://www.benzinga.com/quote/HCA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Amy Li downgraded the rating for Ironwood Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) from Buy to Hold and cut the price target from $8 to $0.7. Ironwood Pharmaceuticals shares closed at $0.6479 on Monday. <a href="https://www.benzinga.com/quote/IRWD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jones Trading analyst Catherine Novack downgraded the rating for Rallybio Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) from Buy to Hold. Rallybio shares closed at $0.2702 on Monday. <a href="https://www.benzinga.com/quote/RLYB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Dan Levy downgraded Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) from Overweight to Equal-Weight and cut the price target from $22 to $14. Mobileye Global shares closed at $12.94 on Monday.  <a href="https://www.benzinga.com/quote/MBLY/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying GM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15082139/image-112-1024x587.png" alt="" class="wp-image-872090" style="width:609px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15082139/image-112-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15082139/image-112-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15082139/image-112-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/15082139/image-112.png 1085w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44806916/citigroup-bank-of-america-and-3-stocks-to-watch-heading-into-tuesday">Citigroup, Bank Of America And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Trading Ideas

MBLY

RLYB

This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Jefferies analyst Amy Li downgrades Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) from Buy to Hold and lowers the price target from $8 to $0.7.

Jefferies Downgrades Ironwood Pharmaceuticals to Hold, Lowers Price Target to $0.7

Leerink Partners analyst Faisal Khurshid maintains Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) with a Market Perform and lowers the price target from $3 to $1.

Leerink Partners Maintains Market Perform on Ironwood Pharmaceuticals, Lowers Price Target to $1

WIIM

Ironwood Pharmaceuticals shares are trading lower after the company announced that the FDA wants a confirmatory Phase 3 trial to approve apraglutide for short bowel syndrome with intestinal failure.

Ironwood Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) on Monday announced that the U.S. Food and Drug Administration (FDA) wants a confirmatory Phase 3 trial to approve apraglutide for short bowel syndrome <a href="https://www.benzinga.com/general/health-care">with intestinal failure</a>.
Ironwood has engaged Goldman Sachs Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44785200/ironwood-pharmaceuticals-provides-clinical-and-regulatory-update-on-apraglutide" rel="noreferrer noopener">explore strategic alternatives</a>.
Apraglutide is a once-weekly, long-acting synthetic GLP-2 analog with the potential to treat rare gastrointestinal diseases.
In preparation for the new drug application (NDA) submission, pharmacokinetic analysis indicated that the exposure and dose delivered in the STARS Phase 3 trial were lower than planned due to dose <a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/37399087/why-is-gastrointestinal-healthcare-focused-ironwood-pharmaceuticals-stock-sinking-on-thursday" rel="noreferrer noopener">preparation and administration</a>.
Based on the strength of the STARS Phase 3 results, Ironwood believed there was a regulatory path forward.
Following a recent dialogue with the FDA, the company said a confirmatory Phase 3 trial is needed to seek approval.
Ironwood plans to work with the FDA on designing a confirmatory Phase 3 trial and the regulatory path forward.
Apraglutide generated strong safety and efficacy data in the STARS Phase 3 trial. Following an analysis of long-term extension trial data, 27 apraglutide-dosed patients dependent on parenteral support achieved enteral autonomy, which is the ultimate goal for these patients. Consistent with FDA discussions, Ironwood plans to continue the long-term extension trial and believes the data from the STARS trial will continue to be an integral part of an NDA submission package.
&#8220;We are disappointed in this outcome,&#8221; Tom McCourt, CEO of Ironwood. 
Apraglutide has the potential to provide &#8220;tremendous value to patients with SBS-IF who suffer from increased mortality and reduced quality of life,&#8221; McCourt added.
Ironwood initiated the rolling new drug application to the FDA for apraglutide for SBS, with submission completion <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b44002403/ironwood-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-results-achieves-2024-financial" rel="noreferrer noopener">expected in Q3 2025</a>.
Price Action: IRWD stock is down 30.28% at 66 cents at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44775286/tariffs-may-have-mixed-effects-on-carmax-may-boost-used-car-demand-due-to-pricier-new-cars-analyst" target="_blank" rel="noreferrer noopener">Tariffs May Have Mixed Effects On Carmax, May Boost Used Car Demand Due To Pricier New Cars: Analyst</a></li>
</ul>
Image: Shutterstock

Biotech

Health Care

General

Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares moved upwards by 68.6% to $0.04 during Monday's regular session. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock rose 54.25% to $0.19. The market value of their outstanding shares is at $5.7 million. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) stock increased by 39.56% to $5.08. The company's market cap stands at $229.1 million. </li>
<li>Metsera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) shares increased by 34.27% to $18.8. The market value of their outstanding shares is at $1.9 billion. </li>
<li>Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>) stock increased by 31.14% to $3.79. The company's market cap stands at $196.8 million. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) stock increased by 29.1% to $0.86. The company's market cap stands at $69.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock fell 30.0% to $0.66 during Monday's regular session. The market value of their outstanding shares is at $105.9 million. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock declined by 22.36% to $0.24. The market value of their outstanding shares is at $19.9 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares declined by 21.84% to $5.07. The market value of their outstanding shares is at $275.5 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares decreased by 17.92% to $0.38. The company's market cap stands at $4.2 million. </li>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) shares declined by 17.62% to $1.73. The company's market cap stands at $16.2 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares decreased by 17.58% to $0.95. The company's market cap stands at $1.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALMS

APDN

BFRG

IMAB

MTSR

RSLS

STSS

THRD

WGRX

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Monday's Intraday Session

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Monday.
The Dow traded up 0.43% to 40,384.20 while the NASDAQ gained 0.33% to 16,778.86. The S&amp;P 500 also rose, gaining, 0.55% to 5,392.71.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/04/44787507/how-to-earn-500-a-month-from-bank-of-america-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Bank of America Stock Ahead Of Q1 Earnings</a>
Leading and Lagging Sectors Information technology shares surged by 2% on Monday.
In trading on Monday, consumer discretionary shares rose by just 0.6%.
Top Headline
M&amp;T Bank Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) posted weaker-than-expected earnings for its first quarter.
M&amp;T Bank reported quarterly earnings of $3.38 per share which missed the analyst consensus estimate of $3.40 per share. The company reported quarterly sales of $2.31 billion which missed the analyst consensus estimate of $2.34 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Longevity Health Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares shot up 67% to $0.2251 after the company announced its merger agreement with 20/20 Biolabs. The closing equity value of the combined companies is $99 million.</li>
<li>Shares of USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>)got a boost, surging 40% to $11.64.</li>
<li>Theratechnologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THTX#NASDAQ">THTX</a>) shares were also up, gaining 39% to $2.7049 after receiving an acquisition proposal from Future Pak. Soleus Capital has issued a letter to shareholders stating that the deal is in their best interest.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Ironwood Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) shares dropped 34% to $0.6215. Ironwood said feedback from the FDA indicates that confirmatory Phase 3 trial is needed to seek approval of Apraglutide for patients with SBS with intestinal failure.</li>
<li>Shares of Mixed Martial Arts Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMA#NYSE">MMA</a>) were down 28% to $1.0996. Mixed Martial Arts Group shares jumped 92% on Friday after the company announced it had entered into a non-dilutive and unsecured $2 million revolving loan agreement.</li>
<li>MarineMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>) was down, falling 8% to $17.36. Truist Securities analyst Michael Swartz maintained MarineMax with a Buy and lowered the price target from $38 to $26.</li>
</ul>
Commodities In commodity news, oil traded down 0.8% to $60.99 while gold traded down 0.8% at $3,219.90.
Silver traded up 0.3% to $32.020 on Monday, while copper rose 1.3% to $4.5830.
Euro zone
European shares were higher today. The eurozone's STOXX 600 jumped 2.52%, Germany's DAX 40 gained 2.80% and France's CAC 40 climbed 2.40%. Spain's IBEX 35 Index surged 2.30%, while London's FTSE 100 rose 2.00%.
Asia Pacific Markets
Asian markets closed higher on Monday, with Japan's Nikkei 225 gaining 1.18%, China's Shanghai Composite gaining 0.76% and Hong Kong's Gang Seng index rising 2.40%.
Economics
Data on consumer inflation expectations will be released today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44787747/wall-streets-most-accurate-analysts-spotlight-on-3-consumer-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Consumer Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

THTX

USAR

Crude Oil Moves Lower; M&T Bank Earnings Miss Views

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 2% on Monday.
The Dow traded up 0.99% to 40,610.00 while the NASDAQ gained 2.02% to 17,062.41. The S&amp;P 500 also rose, gaining, 1.48% to 5,442.94.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/04/44787507/how-to-earn-500-a-month-from-bank-of-america-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Bank of America Stock Ahead Of Q1 Earnings</a>
Leading and Lagging Sectors Information technology shares surged by 2.2% on Monday.
In trading on Monday, consumer staples shares rose by just 0.5%.
Top Headline
The Goldman Sachs Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) posted better-than-expected earnings for its first quarter.
Goldman Sachs reported quarterly earnings of $14.12 per share which beat the analyst consensus estimate of $12.35 per share. The company reported quarterly sales of $15.06 billion which beat the analyst consensus estimate of $14.81 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Longevity Health Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares shot up 92% to $0.2611 after the company announced its merger agreement with 20/20 Biolabs. The closing equity value of the combined companies is $99 million.</li>
<li>Shares of Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>)got a boost, surging 62% to $0.0404.</li>
<li>Theratechnologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THTX#NASDAQ">THTX</a>) shares were also up, gaining 45% to $2.8250 after receiving an acquisition proposal from Future Pak. Soleus Capital has issued a letter to shareholders stating that the deal is in their best interest.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Ironwood Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) shares dropped 36% to $0.6007. Ironwood said feedback from the FDA indicates that confirmatory Phase 3 trial is needed to seek approval of Apraglutide for patients with SBS with intestinal failure.</li>
<li>Shares of Mixed Martial Arts Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMA#NYSE">MMA</a>) were down 28% to $1.0996. Mixed Martial Arts Group shares jumped 92% on Friday after the company announced it had entered into a non-dilutive and unsecured $2 million revolving loan agreement.</li>
<li>UTime Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) was down, falling 26% to $1.5874 after jumping 62% on Friday.</li>
</ul>
Commodities In commodity news, oil traded up 0.7% to $61.95 while gold traded down 0.9% at $3,214.10.
Silver traded down 0.4% to $31.770 on Monday, while copper rose 1.4% to $4.5840.
Euro zone
European shares were higher today. The eurozone's STOXX 600 jumped 2.5%, Germany's DAX 40 gained 2.7% and France's CAC 40 climbed 2.5%. Spain's IBEX 35 Index surged 2.1%, while London's FTSE 100 rose 1.9%.
Asia Pacific Markets
Asian markets closed higher on Monday, with Japan's Nikkei 225 gaining 1.18%, China's Shanghai Composite gaining 0.76% and Hong Kong's Gang Seng index rising 2.40%.
Economics
Data on consumer inflation expectations will be released today.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44787747/wall-streets-most-accurate-analysts-spotlight-on-3-consumer-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Consumer Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Nasdaq Surges 2%; Goldman Sachs Posts Upbeat Earnings

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock increased by 76.0% to $0.04 during Monday's pre-market session. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) shares increased by 37.36% to $5.0. The company's market cap stands at $225.5 million. </li>
<li>Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) shares increased by 32.2% to $4.31. The company's market cap stands at $382.7 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares moved upwards by 27.6% to $0.16. The market value of their outstanding shares is at $4.7 million. </li>
<li>Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) shares rose 26.52% to $1.04. The market value of their outstanding shares is at $3.3 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock increased by 22.3% to $0.2. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Gyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) shares declined by 17.4% to $6.21 during Monday's pre-market session. The company's market cap stands at $581.3 million. </li>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock fell 16.45% to $0.79. The market value of their outstanding shares is at $126.4 million. </li>
<li>Virax Biolabs Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAX#NASDAQ">VRAX</a>) shares declined by 14.18% to $0.95. The company's market cap stands at $4.1 million. </li>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) shares decreased by 12.67% to $1.24. The company's market cap stands at $3.3 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock declined by 11.7% to $0.26. The company's market cap stands at $1.9 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) stock declined by 11.61% to $2.21. The company's market cap stands at $4.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARTL

GYRE

KTTA

MSPR

PTIX

VERV

VRAX

12 Health Care Stocks Moving In Monday's Pre-Market Session

– Feedback from recent FDA interaction indicates that a confirmatory Phase 3 trial evaluating apraglutide in SBS-IF is needed to seek approval –
– Company has engaged Goldman Sachs &amp; Co. LLC to explore strategic alternatives –
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ironwoodpharma.com%2F&amp;esheet=54237597&amp;newsitemid=20250414687154&amp;lan=en-US&amp;anchor=Ironwood+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=1ac4b24b2b9c6afb025e8a0341d2a3d4">Ironwood Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that, based on a recent discussion with the U.S. Food and Drug Administration (FDA), a confirmatory Phase 3 trial is needed to seek approval of apraglutide for patients with short bowel syndrome (SBS) with intestinal failure (IF) who are dependent on parenteral support. While continuing to advance apraglutide, Ironwood has engaged Goldman Sachs &amp; Co. LLC to explore strategic alternatives for the company to maximize value for stockholders.

Ironwood Says Feedback From FDA Indicates That Confirmatory Phase 3 Trial Is Needed To Seek Approval Of Apraglutide For Patients With SBS With Intestinal Failure

Ironwood Pharmaceuticals Receives Letter Of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing

<ul>
<li>Ironwood 2025 Financial Guidance. Ironwood continues to expect:</li>
</ul>
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">
2025 Guidance
(February 2025)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">U.S. LINZESS Net Sales</td>
<td colspan="1" rowspan="1">
$800 - $850 million
High single digit prescription demand growth, more than offset by expected price erosion due to Medicare Part D redesign
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Revenue1</td>
<td colspan="1" rowspan="1">$260 - $290 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA2</td>
<td colspan="1" rowspan="1">&gt;$85 million</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">1 Ironwood's U.S. collaborative arrangements revenue includes reimbursement from AbbVie for a portion of Ironwood's commercial expenses related to sales of LINZESS in the U.S. The FY2025 total revenue guidance accounts for the impact of the reduction to Ironwood's commercial expenses and corresponding reimbursement from AbbVie due to Ironwood's strategic reorganization.</td>
</tr>
</tbody>
</table>
</figure>

Ironwood Pharmaceuticals 2025 Outlook: Expects Revenue Of $260M–$290M Vs. $287.583M Est., Sees Adjusted EBITDA Above $85M

Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.08 by 75 percent. The company reported quarterly sales of $90.55 million which missed the analyst consensus estimate of $93.82 million by 3.49 percent. This is a 22.98 percent decrease over sales of $117.55 million the same period last year.

Earnings Misses

Ironwood Pharmaceuticals Q4 2024 Adj EPS $0.02 Misses $0.08 Estimate, Sales $90.55M Miss $93.82M Estimate

AAON

ABCL

ACEL

ACHC

ACHR

ACIC

ACIW

ADSK

AIRG

ALEX

ALHC

ALKT

ALTM

AMBP

AMPH

AMRC

AMWD

ARGX

ARLO

ARRY

ASTH

AUPH

AVPT

BBWI

BCSF

BECN

BLND

BWMX

CABO

CARS

CCOI

CDXS

CLCO

CLOV

CMBT

CMLS

CMPS

CODI

COLL

CRDF

CRNX

CRON

CSTL

CTKB

CUBE

CVEO

CYTK

DAIO

DCGO

DELL

DUOL

ECVT

EFXT

ERIE

Embraer-Empresa Brasileira De Aeronautica

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

GBTG

GDEN

GDOT

GDRX

Earnings Scheduled For February 27, 2025

S&amp;P 500 constituent Lennar Corp is spinning off Millrose Properties in a transaction expected to be completed on Friday, February 7.&nbsp;
Following the spin-off, Lennar will remain in the S&amp;P 500, and Millrose Properties, which is more representative of the small cap market space, will be added to the S&amp;P SmallCap 600. Ironwood Pharmaceuticals is no longer representative of the small-cap market space.

MRPw

Millrose Properties To Replace Ironwood Pharmaceuticals In S&P SmallCap 600, Effective Prior To  Opening Of Trading On February 10

Ironwood Pharmaceuticals shares are trading lower. The company board announced approval for a 50% reduction in the workforce.

JMP Securities analyst Roy Buchanan maintains Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) with a Market Outperform and lowers the price target from $23 to $14.

JMP Securities Maintains Market Outperform on Ironwood Pharmaceuticals, Lowers Price Target to $14

Press Releases

Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference

Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future

Millrose Properties Set to Join S&P SmallCap 600

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance

Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

Comments

Ironwood Pharmaceuticals

Vendite allo scoperto

Ironwood Pharmaceuticals (NASDAQ:IRWD) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO